Beilstein J. Nanotechnol.2024,15, 333–349, doi:10.3762/bjnano.15.30
still required regarding a realistic use of nanomedicines effective against CD.
Keywords: benznidazole; liposomes; nanocrystals; nanomedicines; nanoparticles; Trypanosomacruzi; Introduction
Nanomedicines are used to solve the problems posed by poor solubility and/or permeability and high toxicity of
nanomedicines against CD will be critically analyzed.
Review
Chagas disease, a threat no longer limited to developing countries
Chagas disease is a parasitic, systemic, chronic, and often fatal infection caused by the protozoan Trypanosomacruzi [4]. The World Health Organization classifies CD as the most
PDF
Figure 1:
A search conducted on PubMed (17 November 2023), employing the following keywords (articles make no...
Beilstein J. Nanotechnol.2023,14, 804–818, doi:10.3762/bjnano.14.66
in the chronic stage, possibly because current treatment regimens do not eradicate transiently dormant Trypanosomacruzi amastigotes. Nanostructured lipid carriers (NLC) appear to be a promising approach for delivering pharmaceutical active ingredients as they can have a positive impact on
. These results show potential for the development of new nanomedicines against T. cruzi.
Keywords: benznidazole; biopharmaceutical study; Chagas disease; nanoparticles; nanostructured lipid carriers; physicochemical characterization; Trypanosomacruzi; Introduction
Chagas disease is a neglected disease
]. It is caused by the hemoflagellate protozoan Trypanosomacruzi, whose life cycle involves transitioning from non-flagellated multiplicative intracellular forms (amastigotes) to blood-circulating non-multiplicative forms (trypomastigotes). It is mainly transmitted by an insect vector of the